Slide 1: Results Presentation - Full Year Ended 31 Dec 2018
RESULTS PRESENTATION For personal use only FULL YEAR ENDED 31 DEC 2018 22 Feb 2019
Slide 2: Vita Life Sciences Overview
VITA LIFE SCIENCES OVERVIEW For personal use only • Australian & Asia Pacific based pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements • 3 major consumer retail brands • 750-800 registered SKUs of vitamin
Slide 3: FY 2018 - Group Summary
FY 2018 - GROUP SUMMARY For personal use only • Group sales of $41.1 million for the financial year (FY) ended Dec 2018, an increase of 10.6% over the previous corresponding period (PCP) of $37.2 million • The Group recorded an underlying EBIT of $6.2m (excluding a non-cash fair value loss adjustmen
Slide 4: Key Financial Charts
Key Financial Charts For personal use only Sales EBIT* EPS ($’m) (cps) ($’m) 45 7 6 40 6 5 35 5 30 4 4 25 3 20 3 5.21 4.44 15 2 2 10 1 1 5 0 0 0 2018 2017 2018 2017 2018 2017 * Underlying EBIT excluding fair value loss on building of $1.8m in 2018 (2017: excluding share options expense of $0.9m)
Slide 5: Full Year 2018 Results - Revenue by Geography
FULL YEAR 2018 RESULTS For personal use only 2018 revenue by geography 2017 revenue by geography Other Australia Other Asia Australia Asia 40% 7% 41% 7% Singapore Singapore 17% 17% Asia Asia 60% 59% Malaysia 36% Malaysia 35% Total revenue: $41.1m Total revenue: $37.2m
Slide 6: Segment Results - Australia
SEGMENT RESULTS Sales ($’m) AUSTRALIA 16.0 For personal use only 12.0 H2 H2 Sales: $16.4m (2017: $15.6m) 8.0 Revenue base business grew despite a highly competitive Australian market conditions H1 4.0 H1 Moderate increase in export sales from Australia to China through the “daigou” channel - 201
Slide 7: Segment Results - Malaysia
Sales ($’m) SEGMENT RESULTS 16 MALAYSIA 12 H2 For personal use only H2 8 Sales $14.9m (2017: $12.9m) 4 Revenue base increased by 15.5% due to rejuvenated consumer H1 H1 pull through trade activities 0 Increased distribution of the VitaHealth brand through modern 2018 2017 trade pharmacies EBIT (
Slide 8: Segment Results - Singapore
Sales ($’m) SEGMENT RESULTS SINGAPORE 6 For personal use only H2 H2 4 2 H1 H1 Sales $6.9m (2017: $6.3m) Revenue base business was sustained generating marginal 0 growth on (PCP) 2018 2017 Increased trade investment was required to maintain sales EBIT ($’m) momentum 2 EBIT $1.6m (2017: $1.4m) E
Slide 9: Segment Results - Others
SEGMENT RESULTS OTHERS For personal use only Sales ($’m) Sales $2.9m (2017: $2.4m) Revenue in other markets growth of 19% (PCP) H2 2 Stronger sales were recorded for Vietnam with marginal H2 improvement in Thailand compared to the PCP Vietnam continues to perform to expectation and is expected
Slide 10: Final Dividend & Cashflow
FINAL DIVIDEND & CASHFLOW For personal use only • Final dividend declared of 2.25 cents per share for FY 2018 (2017: 2.25 cents) • Final dividend will be fully franked. Directors anticipate future dividends to be fully franked. • Dividend reinvestment plan is currently suspended Gross operating Divi
Slide 11: Strategic Priorities and Outlook
Strategic Priorities and Outlook For personal use only • 2019 will see Herbs of Gold launched into selected Pharmacies within the Australian market • Continued branding and promotional investment of VitaHealth and Herbs of Gold brands within core markets • South East Asia markets especially Vietnam,
Slide 12: Appendix
For personal use only APPENDIX
Slide 13: Appendix - Profit & Loss
APPENDIX 1 – PROFIT & LOSS For personal use only Full year ended Dec 2018 2017 $’m $’m Revenue 41.1 37.2 EBITDA 6.6 5.0 EBIT 4.4 4.7 Profit before tax 4.3 4.7 Profit after tax 2.4 2.8 EPS (Basic – cents/ share) 4.44 5.21 Dividend (cents / share) 3.75 3.75
Slide 14: Appendix - Balance Sheet
APPENDIX 2 – BALANCE SHEET For personal use only Balance Sheet as at Dec 2017 Dec 2017 $’m $’m Current assets 24.8 22.3 Non-current assets 10.9 10.6 Total assets 35.7 32.9 Current liabilities 11.4 6.0 Non-current liabilities 1.9 2.1 Total Liabilities 13.3 8.1 Net Assets 22.4 24.8
Slide 15: Appendix - Cash Flow
APPENDIX 3 – CASH FLOW For personal use only Cash Flow for the year ended 2018 2017 $’m $’m Receipts from customers 44.6 40.8 Payments to suppliers and employees 38.1 34.8 Gross operating cash flow 6.5 6.0 Adjusted EBITDA (ex fair value loss adjt & share options exp) 6.6 6.0 Gross operating cash flo
Slide 16: Contact
CONTACT For personal use only Telephone: +61 2 9545 2633 Website: vitalifesciences.com Email: enquiries@vitalifesciences.com Head Office: 1/102 Bath Road, Kirrawee, NSW 2232
Slide 17: Disclaimer
DISCLAIMER For personal use only This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any of